Rates and effectiveness of antiviral use among hospitalized influenza patients

References

• Gwaltney JMJr. Virology and immunology of the common cold. Rhinology 1985;23(4):265-71
   Google Scholar
• Winkler WG. Influenza in animals: its possible public health significance. J Wildl Dis 1970;6(4):239-42
   Google Scholar
• Nosov SD, Ladodo KS. The pathogenesis of influenza. Pediatriia 1964;43:3-9
   Google Scholar
• Cheung TK, Poon LL. Biology of influenza a virus. Ann N Y Acad Sci 2007;1102:1-25
   PubMed Web of Science ®Google Scholar
• Dagut GL. The classification of the virus. Rev Fr Etud Clin Biol 1967;12(9):855-64
   Google Scholar
• Wiwanitkit V. Current research on drugs and vaccines for fighting bird flu. Trans R Soc Trop Med Hyg 2007;101(12):1171-2
   Google Scholar
• Wiwanitkit V. Finding a new drug and vaccine for emerging swine flu: what is the concept? Biologics 2009;3:377-83
   Google Scholar
• Kitamoto O, Tobita K. Therapy of influenza, with special reference to antiviral agents. Naika 1968;22(5):1053-60
   Google Scholar
• Fujii R, Shinozaki T. Chemotherapy for influenza. Naika 1967;19(6):1024-7
   Google Scholar
• Wiwanitkit V. Antiviral drug treatment for emerging swine flu. Clin Ter 2009;160(3):243-5
   Google Scholar
• CDC. Available from: www.cdc.gov/mmwr/%20preview/mmwrhtml/rr6001a1.html
   Google Scholar
• Intharathep P, Laohpongspaisan C, Rungrotmongkol T, et al. How amantadine and rimantadine inhibit proton transport in the M2 protein channel. J Mol Graph Model 2008;27:342-8
   PubMed Web of Science ®Google Scholar
• Monto AS. Antivirals and influenza: frequency of resistance. Pediatr Infect Dis J 2008;27(10 Suppl):S110-12
   Google Scholar
• Nüesch R. Antiviral treatment of influenza in humans. Ther Umsch 2007;64(11):635-41
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009;58(16):433-5
   PubMedGoogle Scholar
• Crusat M, de Jong MD. Neuraminidase inhibitors and their role in avian and pandemic influenza. Antivir Ther 2007;12(4 Pt B):593-602
   Google Scholar
• De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004;30(2):115-33
   PubMed Web of Science ®Google Scholar
• Reece PA. Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 2007;79(10):1577-86
   Web of Science ®Google Scholar
• Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008;78(1):91-102
   PubMedGoogle Scholar
• Wiwanitkit V. Oseltamivir resistance in swine influenza: a brief discussion. N Am J Med Sci 2009;1(3):96-8
   Google Scholar
• Heng PK, Leung TW, Ho EC, et al. Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg Infect Dis 2009;15(6):966-8
   Google Scholar
• Urt AC, Ernest J, Deng YM, et al. Emergence and spread of oseltamivir-resistant A (H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009;83(1):90-3
   Google Scholar
• Arcía J, Sovero M, Torres AL, et al. Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers. Influenza Other Respi Viruses 2009;3(2):69-74
   Google Scholar
• Spanakis N, Pitiriga V, Gennimata V, Tsakris A. A review of neuraminidase inhibitor susceptibility in influenza strains. Expert Rev Anti Infect Ther 2014;12(11):1325-36
   PubMed Web of Science ®Google Scholar
• Wei YN, Zhang C, Chen Q, Guo Y. Drug susceptibility of wild-type and mutant H7N9 neuraminidase to zanamivir and oseltamivir. Bing Du Xue Bao 2014;30(4):396-401
   Google Scholar
• Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza. Med Lett Drugs Ther 2015;57(1461):17-19
   Google Scholar
• Sunagawa S, Higa F, Cash HL, et al. Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics. Influenza Other Respir Viruses 2013;7(1):1-3
   Google Scholar
• Hata A, Akashi-Ueda R, Takamatsu K, Matsumura T. Safety and efficacy of peramivir for influenza treatment. Drug Des Devel Ther 2014;8:2017-38
   PubMed Web of Science ®Google Scholar
• Blaising J, Polyak SJ, Pécheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 2014;107:84-94
   PubMed Web of Science ®Google Scholar
• McKimm-Breschkin JL, Barrett S. Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation. Antiviral Res 2015;114:62-6
   PubMed Web of Science ®Google Scholar
• Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60(1):1-24
   PubMedGoogle Scholar
• Suntarattiwong P, Sojisirikul K, Sitaposa P, et al. Clinical and epidemiological characteristics of respiratory syncytial virus and influenza virus associated hospitalization in urban Thai infants. J Med Assoc Thai 2011;94(Suppl 3):S164-71
   PubMedGoogle Scholar
• Rorat M, Jurek T, Kuchar E, Szenborn L. The clinical course of late diagnosed fatal cases of A (H1N1) influenza in Poland. Postepy Hig Med Dosw (Online) 2013;67:595-600
   Google Scholar
• Abdel-Rahman SM, Newland JG, Kearns GL. Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Paediatr Drugs 2011;13(1):19-31
   PubMed Web of Science ®Google Scholar
• Gauld N, Kelly F, Shaw J. Is non-prescription oseltamivir availability under strict criteria workable? A qualitative study in New Zealand. J Antimicrob Chemother 2011;66(1):201-4
   Google Scholar
• Newton R, King D, Lee H, et al. The national pandemic flu service, oseltamivir, and a case of pancreatitis. BMJ Case Rep 2010;2010; pii: bcr11.2009.2439
   Google Scholar
• Liu CH, Wang JL, Su CP, et al. Oseltamivir use and outcomes during the 2009 influenza A H1N1 pandemic in Taiwan. BMC Public Health 2013;13:646
   Google Scholar
• Machała M, Wiatr E, Gawryluk D, Brydak LB. Significance of virological diagnostics for the effective treatment of hospitalized patients infected with influenza virus. Pneumonol Alergol Pol 2006;74(2):166-70
   PubMedGoogle Scholar
• Tanaka MM, Althouse BM, Bergstrom CT. Timing of antimicrobial use influences the evolution of antimicrobial resistance during disease epidemics. Evol Med Public Health 2014;2014(1):150-61
   Google Scholar
• Huang WT, Chang CH, Hsu YF, Chuang JH. Prognostic factors for mortality in patients hospitalized with influenza complications, in Taiwan. Int Health 2015;7(1):73-5
   Google Scholar
• Hiba V, Chowers M, Levi-Vinograd I, et al. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. J Antimicrob Chemother 2011;66(5):1150-5
   Google Scholar
• Adalja A. Optimization of antiviral prescribing for influenza. J Hosp Med 2009;4(7):E28
   Google Scholar
• Wilkes JJ, Zaoutis TE, Keren R, et al. Treatment with oseltamivir in children hospitalized with community-acquired, laboratory-confirmed influenza: review of five seasons and evaluation of an electronic reminder. J Hosp Med 2009;4(3):171-8
   PubMed Web of Science ®Google Scholar
• Viasus D, Paño-Pardo JR, Pachón J, et al. Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. Chest 2011;140(4):1025-32
   PubMed Web of Science ®Google Scholar
• Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014;2(5):395-404
   PubMed Web of Science ®Google Scholar
• Sugaya N, Sakai-Tagawa Y, Bamba M, et al. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor. Antivir Ther 2014. [Epub ahead of print]
   Google Scholar
• Lee JS, Park SY, Kim JS, et al. The clinical effectiveness of oseltamivir in mild cases of pandemic influenza A H1N1. 2009 infection. Scand J Infect Dis 2012;44(8):595-9
   PubMed Web of Science ®Google Scholar
• Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545
   PubMed Web of Science ®Google Scholar
• Matsuzaki Y, Mizuta K, Aoki Y, et al. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J 2010;7:53
   Google Scholar
• Tran-To Su C, Ouyang X, Zheng J, Kwoh CK. Structural analysis of the novel influenza A. H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivi r, and Peramivir in the presence of mutation R289K. BMC Bioinformatics 2013;14(Suppl 16):S7
   Web of Science ®Google Scholar
• Wang NX, Zheng JJ. Computational studies of H5N1 influenza virus resistance to oseltamivir. Protein Sci 2009;18(4):707-15
   Google Scholar
• Regoes RR, Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006;312(5772):389-91
   PubMed Web of Science ®Google Scholar
• Shetty AK, Ross GA, Pranikoff T, et al. Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient. Pediatr Transplant 2012;16(5):E153-7
   PubMed Web of Science ®Google Scholar
• Wollenhaupt M, Chandrasekaran A, Tomianovic D. The safety of oseltamivir in pregnancy: an updated review of post-marketing data. Pharmacoepidemiol Drug Saf 2014;23(10):1035-42
   Google Scholar
• Jittamala P, Pukrittayakamee S, Tarning J, et al. Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects. Antimicrob Agents Chemother 2014;58(3):1615-21
   PubMed Web of Science ®Google Scholar
• Gupta D, Varghese Gupta S, Dahan A, et al. Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol Pharm 2013;10(2):512-22
   Google Scholar
• Rodríguez A, Alvarez-Rocha L, Sirvent JM, et al. Recommendations of the Infectious Diseases Work Group (GTEI) of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) and the Infections in Critically Ill Patients Study Group (GEIPC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for the diagnosis and treatment of influenza A/H1N1 in seriously ill adults admitted to the Intensive Care Unit. Med Intensiva 2012;36(2):103-37
   Google Scholar
• You JH, Chan ES, Leung MY, et al. A cost-effectiveness analysis of “test” versus “treat” patients hospitalized with suspected influenza in Hong Kong. PLoS One 2012;7(3):e33123
   Web of Science ®Google Scholar
• Lavelle TA, Uyeki TM, Prosser LA. Cost-effectiveness of oseltamivir treatment for children with uncomplicated seasonal influenza. J Pediatr 2012;160(1):67-73
   Google Scholar
• Nagase H, Moriwaki K, Kamae M, et al. Cost-effectiveness analysis of oseltamivir for influenza treatment considering the virus emerging resistant to the drug in Japan. Value Health 2009;12(Suppl 3):S62-5
   Google Scholar